2012-12-05 07:32:32 - Michael Weiner, Professor of Medicine, Radiology and Psychiatry at UCSF Will Be Giving a Featured Presentation Entitled “Using Imaging and CSF Biomarkers in Clinical Alzheimer’s Disease Trials: The Alzheimer's Disease Neuroimaging Initiative (ADNI)” at GTC’s 2nd Neurological Biomarkers Conference, Taking Place in San Francisco, CA on March 20–22, 2013.
Michael Weiner, Professor of Medicine, Radiology and Psychiatry at UCSF will be giving a featured presentation entitled “Using Imaging and CSF Biomarkers in Clinical Alzheimer’s Disease Trials: The Alzheimer's Disease Neuroimaging Initiative (ADNI)” at GTC’s 2nd Neurological Biomarkers Conference, taking place in San Francisco, CA on March 20–22, 2013.
The goal of ADNI has been to determine the value of MRI and PET imaging together with blood and CSF biomarkers for disease modifying Alzheimer’s treatment trials. In the initial project (ADNI1), the group longitudinally studied: MCI (n= 400); AD (n= 200); Controls (n= 220) with clinical visits, neuropsychological assessments, MRI (1.5 T), FDG PET, blood and urine, and CSF. About 300 subjects from ADNI 1 continue to be followed. Similar ADNI-like
projects, with similar methods, are underway in Australia, Japan, Europe, China, Taiwan, and Korea leading to the “World Wide ADNI network.” ADNI methods are now widely used in clinical treatment trials, and have led to the development of the “new” research criteria for AD developed by the Alzheimer’s Association and NIH.
Dr. Weiner attended Johns Hopkins and the State University of New York, and worked at Mt. Sinai Hospital in NY, Yale, U Wisconsin (VA Research Associate, and Clinical Investigatorship) and Stanford (Young Investigator Award of the American College of Cardiology). In 1980 he performed the first experiment using implanted coils to obtain 31P NMR spectra from the kidneys of living rats. Since 1980 he has been at the San Francisco VA Medical Center/UCSF. He is currently Director of the Center for Imaging of Neurodegenerative Disease, a 10,000 sq ft building with one research MRI, and is Professor of Radiology, Medicine, Psychiatry, and Neurology. He has published over 500 papers. His grants include studies of Alzheimer’s disease, vascular dementia, frontotemporal dementia, gulf war illness, posttraumatic stress disorder, HIV, and other neurodegenerative diseases. He is the Principal Investigator of the NIA funded $60 million Alzheimer’s Disease Neuroimaging Initiative. In 2006, Dr. Weiner was awarded the Middleton Award, for outstanding research in the VA. In 2010 he was awarded the Gold Medal of Paul Sabatier University in Toulouse France, and the Gold Medal of the city of Toulouse, France. In 2011 he accepted the Ronald and Nancy Reagan Research Award from the Alzheimer’s Association on behalf of ADNI.
The 2nd Neurological Biomarkers Conference is part of the Biomarker Summit 2013 and provides a unique opportunity to gain the latest biomarker developments in three major therapeutic areas. This conference runs concurrently with two other tracks which are:
6th Oncology Biomarkers
2ndInflammatory & Immunological Biomarkers
The summit will discuss a wide range of issues such as biomarker identification and validation strategies, patient stratification, enabling omics technologies, bioinformatics and systems biology techniques, regulatory and reimbursement trends and the development of companion diagnostics. These areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.
For more information, please visit www.gtcbio.com/biomarkersummit